Drug Discovery

Company plans to produce its own biosimilars, the first of which are already in the advanced development stage.

Companies sought to commercialize mAb CTT-011 since 2006.

Antibody discovery platforms have come a long way since the initial steps toward understanding what antibodies do and how to harness them. GEN recently spoke...

Firm says positive data from CARE-II means U.S. and EU filings for Lemtrada are on track for Q1 2012.

Abbott is paying Seattle Genetics $25 million to expand the firms’ existing antibody-drug conjugate (ADC) alliance. The new deal gives Abbott access to Seattle’s auristatin-based ADC technology for use with antibodies against additional targets.

Phase II/III study will assess 27,000 adults for response to placebo or any of two Ebola vaccine candidates—the partners' rVSV-EBOV, and GSK's cAd3-EBOZ.

Genmab wrapped up an eventful week on Friday as the Danish biotech launched an up to $200 million-per-product cancer therapy collaboration with BliNK Biomedical, and raised $503 million through an American initial public offering (IPO).

The role of adrenaline in triggering the fight-or-flight response is one of the most well-studied phenomena in biology. However, the precise molecular mechanisms for how the hormone stimulates cardiac function have remained unclear. Now a proteomic proximity study had revealed that a protein called Rad dampens the activity of calcium channels.

Company will provide infrastructure support and training.

Biotechnology tool and service companies will continue struggling with reduced demand from the academic segment of their customers and portions of the industry, if a check of third-quarter results is any indication. Details on how this could play out can be read here. Those that are performing well despite the downturn have a portfolio that spans instrumentation, consumables, and services. Last month, Frost & Sullivan issued a report concluding that the global contract research organization market resumed its growth trajectory last year and is expected to grow at a compound annual growth rate of 10.5% until 2017. For vendors dependent on installation of new systems as a primary source of revenue, things don’t look so rosy. Do you think consolidation will be the answer to such companies’ prayers?